

**Medicaid Preferred Drug List (PDL) Program:  
Quarterly Meeting  
Pharmacy and Therapeutics Committee  
Wednesday, June 8, 2005  
9:00 a.m., DMAS Board Room  
REVISED DRAFT AGENDA**

- **Welcome and Introductions** Patrick W. Finnerty, Director
  
  - **Comments from the Secretary of Health and Human Resources** The Honorable Jane H. Woods, Secretary of Health and Human Resources
  
  - **Comments from the Chairperson** Randy Axelrod, M.D., Chairman
  
  - **Acceptance of Minutes** P&T Committee Members  
**From March 23, 2005 P&T Committee Meeting**
  
  - **Open Issues** Patrick W. Finnerty, Director
    - COX-2 Drug Class and FDA Recommendations
  
  - **Drug Class Discussions** P&T Committee Members
- Review of New Drugs in PDL Classes**
- Itraconazole - Onychomycosis Antifungals
  - Felodipine - Calcium Channel Blockers
  - Lunesta<sup>®</sup> - Sedative Hypnotics
  - Fosamax<sup>®</sup> plus D - Bisphosphonates for Osteoporosis
  - Boniva<sup>®</sup> - Bisphosphonates for Osteoporosis
  - Prevacid NapraPAC<sup>®</sup> - Analgesic- NSAIDs
- Review of New Drug Classes for PDL Eligibility**
- Immunomodulators
  - Topical Immunomodulators
  - Electrolyte Depleters
  - Multiple Sclerosis Agents
  - Urinary Tract Antispasmodics
  - Lipotropics Non-Statins: Fibric Acid
  - Lipotropics Non-Statins: Niacin Derivatives
- 
- **Confidential Meeting** Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information
  
  - **Criteria Discussions for New PDL Classes** P&T Committee Members

- **P&T Committee Discussion**

**Randy Axelrod, M.D., Chairman**  
**P&T Committee Members**

- **Next Meeting – TBD**

**Randy Axelrod, M.D., Chairman**